Molecular characterization of ESR1 variants in breast cancer-Reference-Cited by-同舟云学术

Molecular characterization of ESR1 variants in breast cancer

Published:2022-09-20 Issue:2 Volume:196 Page:279-289
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Heeke Arielle L.^ORCID,Elliott Andrew,Feldman Rebecca,O’Connor Hazel F.,Pohlmann Paula R.,Lynce Filipa,Swain Sandra M.,Nunes Maria R.,Magee Daniel,Oberley Matthew J.,Swenson Jeffrey,Vidal Gregory,Isaacs Claudine,Schwartzberg Lee,Korn W. Michael,Tan Antoinette R.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-022-06740-y.pdf

Reference28 articles.

1. Desantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69:438–451. https://doi.org/10.3322/caac.21583

2. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn H-J, André F, Baselga J, Bergh J, Bonnefoi H, Burstein H, Cardoso F, Castiglione-Gertsch M, Coates AS, Colleoni M, Curigliano G, Davidson NE, Di Leo A, Ejlertsen B, Forbes JF, Galimberti V, Gelber RD, Gnant M, Goldhirsch A, Goodwin P, Harbeck N, Hayes DF, Huober J, Hudis CA, Ingle JN, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Kent Osborne C, Partridge AH, De La Peña L, Piccart-Gebhart MJ, Pritchard KI, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z-M, Smith I, Thürlimann B, Toi M, Tutt A, Viale G, Von Minckwitz G, Watanabe T, Whelan T, Winer EP, Xu B (2015) Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533–1546. https://doi.org/10.1093/annonc/mdv221

3. Rozeboom B, Dey N, De P (2019) ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. Am J Cancer Res 9:2821–2831

4. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836–1846. https://doi.org/10.1056/nejmoa1701830

5. Ma CX, Reinert T, Chmielewska I, Ellis MJ (2015) Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer 15:261–275. https://doi.org/10.1038/nrc3920

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes;Endocrinology;2024-08-27

2. CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape;npj Breast Cancer;2024-02-22

3. Systematic analysis of DNA methylation-mediated TF dysregulation on lncRNAs reveals critical roles in tumor immunity;Molecular Therapy - Nucleic Acids;2023-12

4. Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors;Clinical Cancer Research;2023-06-08

5. Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer;Cancer Research;2023-04-18